Radiographic outcomes through 2 years
| Year 1 | Year 2 | |||
|---|---|---|---|---|
| SC abatacept (n=295) | Adalimumab (n=297) | SC abatacept (n=257) | Adalimumab (n=260) | |
| Total score | ||||
| Mean change from baseline (SD) | 0.56 (2.62) | 0.74 (6.57) | 0.89 (4.13) | 1.13 (8.66) |
| Erosion score | ||||
| Mean change from baseline (SD) | 0.21 (1.81) | 0.25 (3.80) | 0.41 (2.57) | 0.41 (5.04) |
| Joint space narrowing score | ||||
| Mean change from baseline (SD) | 0.35 (1.67) | 0.50 (3.03) | 0.48 (2.18) | 0.72 (3.81) |
| Radiographic non-progressors | ||||
| Change from baseline ≤SDC | 87.8% | 88.6% | 84.8% | 83.8% |
| Change from baseline ≤0.5 | 71.2% | 77.8% | 70.8% | 73.1% |
SC, subcutaneous; SDC, smallest detectable change.